ClinicalTrials.gg
CompletedNCT07717918Updated Sep 10, 2026

A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants

A Phase 1 interventional study of BL1332 eye drops and BL1332 Placebo eye drops in Healthy, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.

First submitted after Bausch & Lomb Incorporated became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 65 years of age.
  • In good health, as assessed at Screening by the Investigator from past medical history, physical examination (abbreviated), and laboratory tests.
  • Does not wear contact lenses, or is willing to refrain from wearing contact lenses for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Women of or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of and agree to use an effective method of contraception until at least 30 days after study treatment.
  • Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator, preclude the safe administration of IP, safe participation in this study, or confound the assessment of safety or efficacy.
  • Unwilling or unable to comply with the study protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    BL1332 eye drops

    Drug: BL1332 eye drops

  • Placebo comparator
    BL1332 Placebo eye drops

    Drug: BL1332 Placebo eye drops

Interventions

  • DrugBL1332 eye drops

    Taken 1 time

  • DrugBL1332 Placebo eye drops

    Taken 1 time

06

What researchers measure

Primary outcomes

  1. Ocular pain severity assessed by numeric pain rating scale (NPRS)

    NPRS scale 0 to 10, with higher score reflecting worse pain

    Time frame: Assessed 5 seconds post-capsaicin dose

07

Study locations

1 site
  • Site 101
    Newport Beach, California 92663, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Aug 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartActual
Jul 6, 2026
Primary completionActual
Aug 5, 2026
CompletionActual
Aug 5, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07717918
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Jul 6, 2026
Primary completion
Aug 5, 2026
Completion
Aug 5, 2026
Last update
Sep 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion